Andrea Mahr

Tuebingen, Germany

Andrea Mahr

Average Co-Inventor Count = 6.0

ph-index = 17

Forward Citations = 1,872(Granted Patents)

Forward Citations (Not Self Cited) = 948(Sep 21, 2024)

DiyaCoin DiyaCoin 1.51 

Inventors with similar research interests:


Location History:

  • Tübingen, DE (2018 - 2021)
  • Tuebingen, DE (2014 - 2024)


Years Active: 2014-2025

where 'Filed Patents' based on already Granted Patents

348 patents (USPTO):
1 patent (CIPO):

Title: Andrea Mahr: A Pioneer in Immunotherapeutic Treatment of Cancer

Introduction:

Andrea Mahr, based in Tuebingen, DE, is a distinguished figure in the field of immunotherapy and cancer research. With an impressive portfolio of 279 patents, Mahr has made significant contributions to the development of peptides, proteins, nucleic acids, and cells for use in immunotherapeutic methods. This article will delve into Mahr's latest patents, career highlights, collaborations, and their impactful work in advancing cancer treatments through immunotherapy.

Latest Patents:

Mahr's recent patents focus on the use of peptides and T cells in the immunotherapeutic treatment of various cancers. These patents reveal groundbreaking research on tumor-associated T-cell epitopes and their potential as active pharmaceutical ingredients in vaccine compositions. The aim is to stimulate anti-tumor immune responses and transfer T cells ex vivo into patients. This innovative approach has the potential to revolutionize cancer treatment and improve patient outcomes.

Career Highlights:

Throughout their career, Mahr has been associated with renowned biotechnology companies, including Immatics Biotechnologies GmbH. Immatics Biotechnologies is at the forefront of developing novel immunotherapies for various types of cancers. Mahr's association with such organizations highlights their dedication to cutting-edge research and development in the field of immunotherapy.

Collaborations:

Mahr has also collaborated closely with esteemed professionals in the field. Notably, they have worked with Toni Weinschenk and Jens Fritsche, two respected figures in the field of cancer immunotherapy. These collaborations have fostered an exchange of ideas and expertise, driving scientific advancements and leading to impactful research outcomes.

Conclusion:

Andrea Mahr's exceptional contributions to the field of immunotherapy and cancer research have made a lasting impact. Their extensive patent portfolio, particularly in the field of peptides and T cells, demonstrates a commitment to finding new and effective ways to combat cancer. Mahr's career highlights and collaborations further exemplify their expertise and dedication in pushing the boundaries of cancer treatment. As the field of immunotherapy continues to evolve, Mahr's work serves as an inspiration for future innovators in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…